Sensor incorporating a quantum dot as a reference

• US 6,379,622 B1
• Filed: 04/11/2001
• Issued: 04/30/2002
• Est. Priority Date: 04/11/2001
• Status: Expired due to Term

• Current Assignee: Cilag Gmbh International (Johnson & Johnson)
• Original Assignee: Motorola, Inc. (Motorola Solutions, Inc.)
• Inventors: Zhu, Ji, Polak, Anthony
• Primary Examiner(s): Chin, Christopher L.
• Assistant Examiner(s): Counts, Gary W.
• Application Number:
  US09/832,538
• Time in Patent Office: 384 Days
• Field of Search: 422/82.06, 422/82.07, 422/82.08, 422/82.09, 422/82.11, 422/101, 250/307, 250/364, 250/458.1, 250/440.11, 250/338.4, 250/438, 435/7.1, 356/45, 356/445, 356/300, 356/243.1, 356/243.2, 356/243.8, 600/317, 600/341, 436/518
• US Class Current: 422/82.06
• CPC Class Codes: B82Y 10/00 Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• CPC Class Codes: B82Y 20/00 Nanooptics, e.g. quantum optics or photonic crystals
• CPC Class Codes: G01N 21/6428 Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" in vivo A61B5/00; immunoassay G01N33/53

Abstract

The present invention provides a device and methods for quantitatively detecting the presence of an analyte by referencing the analyte variant signal to an analyte invariant reference signal. The devices contain quantum dots as the invariant references. The reference quantum dots provide a fluorescent signal whose intensity in invariant with respect to the optical signal associated with the analyte concentration. Both the optical path for the analyte specific and invariant reference signal are substantially identical. Therefore, by measuring the intensity ratio of the analyte specific signal to the reference signal, errors associated with optical path length, absorptivity and scattering are eliminated.

Claims

1. A device for detecting the presence of analyte in a sample, comprising:

(a) a binding substrate that has at least one affinity binding site for the analyte and a labeled analogue;

(b) said labeled analogue comprising an analogue and a label, wherein the label emits light at a first wavelength when irradiated;

(c) a dye bound to the binding substrate, which has an absorption spectrum that overlaps a fluorescence excitation and emission spectra of the label;

(d) a first reference comprising quantum dots that emit light at a second wavelength when irradiated;

(e) an analyte-permeable membrane that encapsulates components (a), (b), (c), and (d); and

(f) a void volume exterior to the binding substrate and interior to the analyte-permeable membrane.

2. The device of claim 1, wherein the binding substrate is attached to a support.

3. The device of claim 1, wherein the quantum dot reference is in the analyte-permeable membrane.

4. The device of claim 1, wherein the quantum dot reference is bonded to a surface of the analyte-permeable membrane.

5. The device of claim 1, wherein the quantum dot reference is covalently attached to the analyte-permeable membrane.

6. The device of claim 1, wherein the quantum dot reference is attached to the binding substrate.

7. The device of claim 1, wherein the void volume is formed by a spacer between the analyte permeable membrane and the binding substrate.

8. The device of claim 7, wherein the quantum dot reference is attached to the spacer.

9. The device of claim 1, wherein the quantum dots comprise at least one Group II-VI semiconductor compound, Group III-V semiconductor compound, or organic semiconductor compound.

10. The device of claim 1, wherein the quantum dots comprise at least one semiconductor compound selected from the group consisting of MgS, MgSe, MgTe, CaS, CaSe, CaTe, SrS, SrSe, SrTe, BaS, BaSe, BaTe, ZnS, ZnSe, ZnTe, CdS, CdSe, CdTe, HgS, HgSe, HgTe, GaAs, InGaAs, InP, InAs, Ge, and Si.

11. The device of claim 1, wherein the quantum dots have an average cross-section no larger than about 60 Å

.

12. The device of claim 1, wherein the quantum dots have an average cross-section no larger than about 50 Å

.

13. The device of claim 1, wherein the quantum dots have an average cross-section of about 1 to 50 Å

.

14. The device of claim 1, wherein the quantum dots have an average cross-section of about 10 to 50 Å

.

15. The device of claim 1, wherein the analyte is selected from the group consisting of glucose, coumadin, synthroid, cyclosporin, erythropoietin, lopid, monopril, digoxin, amiodarone, prothrombin, cytokines, chemokines, creatinine, lactate, taxol, and fluorouracil.

16. The device of claim 1, wherein the analyte is glucose.

17. The device of claim 16, wherein the analyte-permeable membrane is cellulose acetate.

18. The device of claim 16, wherein the analogue is Concanavalin-A.

19. The device of claim 16, wherein the label is ALEXA™

633.

20. The device of claim 1, wherein the analyte-permeable membrane is selected from the group consisting of cellulose acetate, polysulfones, polycarbonates, poly(vinyl chlorides), polyamides, ethylene vinyl acetate copolymers, poly(vinylidene) fluoride, poly(urethanes), poly(benzimidazoles), cellulose esters, cellulose triacetate, cellulose, cellulose nitrate, regenerated cellulose, cross-linked poly(vinylpyrrolidone);

crosslinked polyacrylamide, crosslinked poly (hydroxy ethyl methacrylate), silicones, fluorosiloxanes, and polytetrafluoroethylene or combinations thereof.

21. The device of claim 20, wherein the analyte-permeable membrane is coated with at least one substance that promotes biocompatibility.

22. The device of claim 21, wherein the analyte-permeable membrane is coated with polyethylene glycol or an angiogenic substance.

23. The device of claim 21, wherein the analyte-permeable membrane is coated with basic fibroblast growth factor.

24. The device of claim 1, wherein the analogue is Concanavalin-A or dextran.

25. The device of claim 1, comprising more than one labeled analogue.

26. The device of claim 2, wherein the support is dextran, compounds with a glucose moiety, a metal oxide, metal silicate, metal borate, metal phosphate, or plastic.

27. The device of claim 2, wherein the support is a silicon oxide.

28. The device of claim 1, wherein the support is a bead.

29. A method of quantitatively determining the amount of at least one analyte in a sample, which comprises the steps of:

(a) contacting a sample with the device of claim 1,

(b) irradiating the device with light,

(c) determining the intensity of emission from the labeled analogue,

(d) determining the intensity of emission from the quantum dot reference,

(e) correlating the intensity of emission from (c) and (d) to thereby determine the amount of analyte in the sample.

30. A method of optimizing the signal to noise ratio of an optical sensor, which comprises the steps of:

(a) contacting a sample with the device of claim 1,

(b) irradiating the device with light,

(c) maximizing the labeled analogue signal/noise ratio by optimizing the reference signal intensity by physically moving the excitation source and detector relative to the sensing device.